Valdoxan® today received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients with Major Depressive Episodes (MDE).1 Valdoxan is an innovative approach to the treatment of MDE and has demonstrated convincing efficacy in depressed patients with moderate-severe depression2, offering new hope to many of the more than 2.
Popularity: unranked [?]
Related posts:
- Valdoxan(R) Granted Marketing Authorisation For The Treatment Of Major Depressive Episodes In Europe
- New Melatonergic Antidepressant Combines Efficacy With Very Favourable Side-Effect Profile
- New Melatonergic Antidepressant Combines Efficacy With Very Favourable Side-Effect Profile
- European Medicines Agency Adopts Positive Opinion For Use Of Prozac For Children And Adolescents Suffering From Depression
- Rexahn Pharmaceuticals Receives FDA Approval To Initiate Phase II Trial For Serdaxin In Patients With Major Depressive Disorders
Comments
No Responses to “Novel Antidepressant Valdoxan(R), Receives EMEA CHMP Positive Opinion For Major Depressive Episodes”